Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Abivax S.A. clinical trials
The registry lists 23 studies whose lead sponsor is Abivax S.A.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.
Keep track of what changes. Save the Abivax S.A. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Abivax S.A..
- Abivax S.A.23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseRecruitingNCT06456593Phase 2
- Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationRecruitingNCT07453784Phase 1
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaCompletedNCT03897543Phase 1/2
- ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2CompletedNCT05507216Phase 3
- ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1CompletedNCT05507203Phase 3
- ABTECT - MaintenanceActive, not recruitingNCT05535946Phase 3
- Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisCompletedNCT04023396Phase 2
- Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisActive, not recruitingNCT05177835Phase 2
- Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisCompletedNCT03760003Phase 2
- ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19TerminatedNCT04393038Phase 2/3
- Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisCompletedNCT04049448Phase 2
- Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisCompletedNCT03368118Phase 2
- ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentCompletedNCT02735863Phase 2
- Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease PatientsWithdrawnNCT03905109Phase 2/3
- ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisCompletedNCT03093259Phase 2
- ABX464 First in Man StudyCompletedNCT02792686Phase 1
- A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive AdultsCompletedNCT02990325Phase 1/2
- Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT03813199Phase 2
- Safety and Pharmacokinetics Study in Healthy Japanese VolunteersCompletedNCT05032560Phase 1
- Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464CompletedNCT05121714Phase 1
- Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis BCompletedNCT02249988Phase 2/3
- Safety, PK and PD Study of ABX464 in Untreated HIV PatientsCompletedNCT02452242Phase 2
- Food Effect on Pharmacokinetic Parameters of ABX464CompletedNCT02731885Phase 1